Home › Calculator › PCRX Dividend Calculator 2026
PCRX Dividend DRIP Calculator 2026
7.93% YieldHealthcarePacira BioSciences, Inc. · NASDAQ
Price: $25.23 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When PCRX pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your PCRX snowball 📈
$10,000 in PCRX → $1.40M in 10 years · $74.82/month
About Pacira BioSciences, Inc. (PCRX) — Dividend Analysis 2026
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Compare PCRX with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full PCRX DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PCRX position with:
🌍 PCRX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold PCRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 7.93% | 5.13% | $793 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 6.74% | 3.94% | $674 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 6.34% | 3.54% | $634 / yr |
| 🇬🇧 UK ISA | 0% | 7.93% | 5.13% | $793 / yr |
| 🇬🇧 UK Taxable | 8.75% | 7.24% | 4.44% | $724 / yr |
| 🇨🇦 TFSA | 0% | 7.93% | 5.13% | $793 / yr |
| 🇨🇦 CA Taxable | 25% | 5.95% | 3.15% | $595 / yr |
| 🇦🇺 Super (pension) | 15% | 6.74% | 3.94% | $674 / yr |
| 🇦🇺 AU Taxable | 30% | 5.55% | 2.75% | $555 / yr |
| 🇩🇪 DE Taxable | 26.375% | 5.84% | 3.04% | $584 / yr |
| 🇫🇷 FR Taxable | 30% | 5.55% | 2.75% | $555 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 PCRX Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 PCRX Dividend Payment Schedule
PCRX pays quarterly — 4 times per year. Next ex-div: TBD.
📊 PCRX vs Healthcare Benchmarks
How PCRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PCRX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ PCRX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-10 | 10,891 | $23.42 | $255.1K | ||
| A-Award | 2026-06-10 | 6,405 | — | — | ||
| Sale | 2026-06-11 | 6,115 | $23.50 | $143.7K | ||
| A-Award | 2026-06-10 | 6,405 | — | — | ||
| A-Award | 2026-06-10 | 10,891 | $23.42 | $255.1K | ||
| A-Award | 2026-06-10 | 32,675 | $23.42 | $765.2K | ||
| A-Award | 2026-06-10 | 6,405 | — | — | ||
| A-Award | 2026-06-10 | 10,891 | $23.42 | $255.1K | ||
| A-Award | 2026-06-10 | 6,405 | — | — | ||
| A-Award | 2026-06-10 | 10,891 | $23.42 | $255.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PCRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Pacira BioSciences, Inc. (PCRX) is currently trading at $25.23, 68% below its 52-week high. The current dividend yield is 7.93% based on an annual payout of $2.00 per share.
PCRX (Pacira BioSciences, Inc.) — 7.93% Dividend Yield Analysis
Pacira BioSciences, Inc. (PCRX) is a healthcare stock currently trading at $25.23 with a dividend yield of 7.93%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (7.93%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.